“…2,14,22 However, in patients with histologically atypical (WHO grade II) or anaplastic (WHO grade III) tumors, these treatment approaches are almost never curative, with 10-year disease-free survival rates of 13% and 0%, respectively. 14,22 In these patients, treatment with doxorubicin, hydroxyurea, temozolomide, irinotecan, interferon-a, tamoxifen, imatinib, mifepristone, or octreotide acetate have been attempted.…”